Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Special Report
Positives outnumber negatives from March PBAC
Positive recommendations outnumbered rejections from the March PBAC meeting with 19 major submissions given the go-ahead, 12 knocked back and three deferred. Full results inside.
PBS Top Five
Dermatology - Psoriasis drugs dominate
In this new regular feature, we analyse the PBS market by market with the focus on F1 drugs. Inside you'll find the top five dermatology brands, the top five companies in dermatology and the fastest growing brands and companies by both value and volume with growth rates and PBS on-patent dermatology market shares.
Pipeline Monitor
Keytruda in lung cancer bid
MSD's Keytruda, just approved for melanoma in Australia has been filed in the US as a treatment for lung cancer.
Working Life
Money or progress? Survey shows pharma's gender split
Pharma has a gender divide when it comes to asking the big questions around salary, career advancement and flexible working as your answers to our HR survey show.
Approvals Action
MSD facing $26m diabetes challenge
MSD has seen the first rival brands registered against its top-selling gliptin, Januvia while GSK has won approval of an HSA-free version of Varilix.